北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第三临床医学院  > 期刊论文
学科主题: 临床医学
题名:
Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty
作者: Wang, G; Wei, JR; Guan, YF; Jin, N; Mao, JM; Wang, X
刊名: METABOLISM-CLINICAL AND EXPERIMENTAL
发表日期: 2005-05-01
DOI: 10.1016/j.metabol.2004.11.017
卷: 54, 期:5, 页:590-597
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Endocrinology & Metabolism
研究领域[WOS]: Endocrinology & Metabolism
关键词[WOS]: MONOCYTE CHEMOATTRACTANT PROTEIN-1 ; C-REACTIVE PROTEIN ; HUMAN ENDOTHELIAL-CELLS ; PPAR-GAMMA ; IN-VITRO ; GENE-EXPRESSION ; UNSTABLE ANGINA ; ATHEROSCLEROSIS ; TROGLITAZONE ; ATHEROGENESIS
英文摘要:

Rosiglitazone, an agonist of peroxisome proliferator- activated receptor-gamma (PPAR gamma), is an insulin-sensitizing antidiabetic agent and inhibits restenosis in animal blood vessels. However, its benefit for patients with type 2 diabetes and coronary artery disease (CAD) after percutaneous coronary intervention is unknown. Patients with diabetes and CAD who had undergone percutaneous coronary intervention were randomized to either receive or not receive rosiglitazone,(4 mg/d) for 6 months. After 6 months of rosiglitazone treatment, the plasma levels of fasting glucose and insulin and those of hemoglobin A I C and homeostasis model assessment of insulin resistance were significantly decreased in the rosiglitazone group as compared with baseline levels and those in the control group. After 2 and 6 months of rosiglitazone treatment, the plasma level of high-density lipoprotein was significantly increased in the rosiglitazone group. In addition, plasma levels of monocyte chemoattractant protein-1 and C-reactive protein and hyperresponsiveness of low-dose lipopolysaccharide-induced monocyte chemoattractant protein-1 secretion from monocytes were reduced. Furthermore, the occurrence of coronary events was significantly decreased in the rosiglitazone group at 6-month follow-up. Our data indicate that rosiglitazone may protect the vascular wall through not only improving the features of metabolic disorders but also reducing proinflammatory responses and the occurrence of coronary events in patients with diabetes and CAD after percutancous coronary intervention. (c) 2005 Elsevier Inc. All rights reserved.

语种: 英语
WOS记录号: WOS:000229205100006
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/53977
Appears in Collections:北京大学第三临床医学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Dept Physiol, Beijing 100083, Peoples R China
2.Peking Univ, Ins Vasc Med, Third Hosp, Beijing 100083, Peoples R China
3.Peking Univ, Key Lab Mol Cardiovasc Sci, Educ Minist, Hlth Sci Ctr, Beijing 100083, Peoples R China

Recommended Citation:
Wang, G,Wei, JR,Guan, YF,et al. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty[J]. METABOLISM-CLINICAL AND EXPERIMENTAL,2005,54(5):590-597.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Wang, G]'s Articles
[Wei, JR]'s Articles
[Guan, YF]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Wang, G]‘s Articles
[Wei, JR]‘s Articles
[Guan, YF]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace